A cisplatin and vinorelbine (NP) regimen as a postoperative adjuvant chemotherapy for completely resected breast cancers in China: Final results of a phase II clinical trial

Asian Pacific Journal of Cancer Prevention

Volumn 12, Issue 1, 2011, Pages 77-80

  Gao, Li Li ^a   Huang, Xin En ^a   Zhang, Qian ^a   Tang, Jin Hai ^b  

^a People's Hospital of Fu'ning County   (China)

^b JIANGSU CANCER HOSPITAL   (China)

Author keywords

Adjuvant chemotherapy; Breast cancer; Cisplatin; Vinorelbine

Indexed keywords

EID: 79958760253     PISSN: 15137368     EISSN: 2476762X     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Bruno S, Puerto VL, Mickiewicz E, et al. (1995). Phase II trial of weekly i.v. vinorelbine as a single agent in first-line advanced breast cancer chemotherapy. The Latin-American experience. Am Soc Clin Oncol, 18, 392-6
2. Burstein HJ, Kuter I, Campos SM, et al. (2001). Clinical activity of trastuzumab and vinorelbine in women with HER2-overexpressing metastatic breast cancer. J Clin Oncol, 19, 2722-30
3. Camoriano JK, Loprinzi CL, Ingle JN, et al. (1990). Weight change in women treated with adjuvant therapy or observed following mastectomy for node-positive breast cancer. J Clin Oncol, 8, 1327-34
4. Cardoso F, Atalay G, Piccart MJ. (2002). Optimizing anthracycline therapy for node positive breast cancer. Am J Cancer, 1, 257-68
5. Cros S, Wright M, Morimoto M, et al. (1989). Experimental activity of navelbine. Semin Oncol, 16, 15-20
6. Ferlay J, Bray F, Pisani P, et al. (2004). Globocan 2002: Cancer Incidence, mortality and prevalence worldwide, version 2.0. IARC Cancer Base No. 5. Lyon, France: IARC Press
7. Fumoleau P, Delgado FM, Delozier T, et al. (1993). Phase II trial of weekly intravenous vinorelbine in first-line advanced breast cancer chemotherapy. J Clin Oncol, 11, 1245-52
8. Fumoleau P, Fety R, Delecroix V, et al. (1997). Docetaxel combined with vinorelbine: phase II results and new study designs. Oncology, 11, 29-31
9. Garcia-Conde J, Lluch A, Martin M, et al. (1994). Phase II trial of weekly IV vinorelbine in first-line advanced breast cancer chemotherapy. Ann Oncol, 5, 854-7
10. Goodwin PJ, Ennis M, Pritchard KI, et al. (1999). Risk of menopause during the first year after breast cancer diagnosis. J Clin Oncol, 17, 2365-70
11. Gunel N, Akcali Z, Yamac D, et al. (2000). Cisplatin plus vinorelbine as a salvage regimen in refractory breast cancer. Tumori, 86, 283-5
12. Jensen BV. (2006). Cardiotoxic consequences of anthracycline containing therapy in patients with breast cancer. Semin Oncol, 33, S15-21
13. Kaplan EL, Meier P. (1958). Nonparametric estimation from incomplete observations. J Am Stat Assoc, 53, 457-81
14. Klastersky JO, Schulier G, Bureau P, et al. (1989). Cisplatin versus cisplatin plus etoposide in the treatment of advanced non-small cell lung cancer. J Clin Oncol, 7, 1087-92
15. Mamounas EP, Bryant J, Lembersky B, et al. (2005). Paclitaxel after doxorubicin plus cyclophosphamide as adjuvant chemotherapy for node-positive breast cancer: results from NSABP B-28. J Clin Oncol, 23, 3686-96
16. Martin M, Garcia-Donas J, Casado A, et al. (2004). Phase II study of pegylated liposomal doxorubicin plus vinorelbine in breast cancer with previous anthracycline exposure. Clin Breast Cancer, 5, 353-7
17. Nabholtz JM, Falkson C, Campos D, et al. (2003). Docetaxel and doxorubicin compared with doxorubicin and cyclophosphamide as first-line chemotherapy for metastatic breast cancer: results of a randomized, multicenter, phase II trial. J Clin Oncol, 21, 968-75
18. Nabholtz JM, Mackey JR, Smylie M, et al. (2001). Phase II study of docetaxel, doxorubicin, and cyclophosphamide as first-line chemotherapy for metastatic breast cancer. J Clin Oncol, 19, 314-21
19. Ray-Coquard I, Biron P, Bachelot T, et al. (1998). Vinorelbine and cisplatin (CIVIC regimen) for the treatment of metastatic breast carcinoma after failure of anthracycline- and/or paclitaxel-containing regimens. Cancer, 82, 134-40
20. Romero Acuna L, Langhi M, Perez J, et al. (1999). Vinorelbine and paclitaxel as first-line chemotherapy in metastatic breast cancer. J Clin Oncol, 17, 74-81
21. Shamseddine A, Khalifeh M, Chehal A, et al. (2005). A clinical phase II study of cisplatinum and vinorelbine (PVn) in advanced breast carcinoma (ABC). Am J Clin Oncol, 28, 393-8
22. Weber BL, Vogel C, Jones S, et al. (1995). Intravenous vinorelbine as first-line and second-line therapy in advanced breast cancer. J Clin Oncol, 13, 2722-30
23. Yang L, Parkin DM, Ferlay J, et al. (2005). Estimates of cancer incidence in China for 2000 and projections for 2005. Cancer Epidemiol Biomarkers Prev, 14, 243-50
24. Yu KD, Di GH, Wu J, et al. (2007). Development and trends of surgical modalities for breast cancer in China: a review of 16-year data. Ann Surg Oncol, 14, 2502-9.